IS4628A - Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka - Google Patents

Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka

Info

Publication number
IS4628A
IS4628A IS4628A IS4628A IS4628A IS 4628 A IS4628 A IS 4628A IS 4628 A IS4628 A IS 4628A IS 4628 A IS4628 A IS 4628A IS 4628 A IS4628 A IS 4628A
Authority
IS
Iceland
Prior art keywords
pain
treatment
cell series
produces
relieving substances
Prior art date
Application number
IS4628A
Other languages
English (en)
Icelandic (is)
Inventor
Saydoff Joel
Original Assignee
Cyto Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyto Therapeutics, Inc. filed Critical Cyto Therapeutics, Inc.
Publication of IS4628A publication Critical patent/IS4628A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS4628A 1995-06-07 1997-12-04 Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka IS4628A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48191795A 1995-06-07 1995-06-07
PCT/US1996/009629 WO1996040959A1 (en) 1995-06-07 1996-06-07 Cell line producing analgesic compounds for treating pain

Publications (1)

Publication Number Publication Date
IS4628A true IS4628A (is) 1997-12-04

Family

ID=23913905

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4628A IS4628A (is) 1995-06-07 1997-12-04 Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka

Country Status (20)

Country Link
EP (1) EP0833935A1 (en:Method)
JP (1) JPH11507530A (en:Method)
KR (1) KR19990022414A (en:Method)
CN (1) CN1192246A (en:Method)
AR (1) AR004494A1 (en:Method)
AU (1) AU6263696A (en:Method)
BR (1) BR9608746A (en:Method)
CA (1) CA2223246A1 (en:Method)
CZ (1) CZ392497A3 (en:Method)
EE (1) EE9700326A (en:Method)
HU (1) HUP9901191A2 (en:Method)
IL (1) IL122415A0 (en:Method)
IN (1) IN181898B (en:Method)
IS (1) IS4628A (en:Method)
NO (1) NO975545L (en:Method)
PL (1) PL323867A1 (en:Method)
SK (1) SK167997A3 (en:Method)
TR (1) TR199701520T1 (en:Method)
WO (1) WO1996040959A1 (en:Method)
ZA (1) ZA964880B (en:Method)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525168A (ja) * 1997-11-28 2001-12-11 メディカル リサーチ カウンシル ベクター
WO2000016799A1 (en) * 1998-09-23 2000-03-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating chronic pain
DE69928960T2 (de) * 1998-10-27 2006-08-10 Anticancer Inc., San Diego Herstellung eines retrovirus, welches den mel-lokus von streptomyces enthält, sowie dessen expression in säugetierzellen
US6372489B1 (en) 1998-10-27 2002-04-16 Anticancer, Inc. Method and model for hair pigmentation
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
CA2551189A1 (en) 2003-12-24 2005-07-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic agents and uses therefor
EP1766389A4 (en) 2004-05-12 2008-08-27 Inst Medical W & E Hall METHOD OF ISOLATING CELLS
CN101248177B (zh) 2005-06-24 2012-09-05 沃尔特及伊莱萨霍尔医学研究院 治疗性促凋亡bh3样分子和用于产生和/或选择它的方法
EP2051726B1 (en) 2006-07-18 2018-04-18 University of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
KR20160019469A (ko) 2013-05-31 2016-02-19 더 유니버시티 오브 유타 리서치 파운데이션 코노톡신 펩티드, 제약 조성물 및 그의 용도
AU2016345063B2 (en) 2015-10-27 2021-08-05 The Council Of The Queensland Institute Of Medical Research A method of treatment and agents useful for same
CN107964047B (zh) * 2017-12-18 2018-11-02 哈尔滨工业大学 基于内吗啡肽-1和神经降压素(8-13)的嵌合肽及其合成方法和应用
CN112891337A (zh) * 2021-03-26 2021-06-04 河北医科大学 高良姜素及其衍生物在制备预防和治疗神经系统疾病药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2169292C (en) * 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Also Published As

Publication number Publication date
AR004494A1 (es) 1998-12-16
HUP9901191A2 (hu) 1999-08-30
AU6263696A (en) 1996-12-30
CA2223246A1 (en) 1996-12-19
NO975545L (no) 1998-02-04
EP0833935A1 (en) 1998-04-08
CN1192246A (zh) 1998-09-02
SK167997A3 (en) 1998-05-06
PL323867A1 (en) 1998-04-27
BR9608746A (pt) 1999-05-11
ZA964880B (en) 1997-01-07
WO1996040959A1 (en) 1996-12-19
JPH11507530A (ja) 1999-07-06
IL122415A0 (en) 1998-06-15
EE9700326A (et) 1998-06-15
NO975545D0 (no) 1997-12-02
TR199701520T1 (xx) 1998-04-21
IN181898B (en:Method) 1998-10-24
KR19990022414A (ko) 1999-03-25
CZ392497A3 (cs) 1998-12-16

Similar Documents

Publication Publication Date Title
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
ID17156A (id) Zat-zat anti koagulan yang berguna dalam pengobatan trombosis
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
DE69630947D1 (de) Mittel zur schmerzbehandlung
DE69825447D1 (de) Gerät zur dermatologischen behandlung
IS4628A (is) Frumuröð sem myndar kvalastillandi efni til nota í meðferð gegn sársauka
EP0925046A4 (en) TOPICAL PREPARATIONS AND METHODS FOR TREATING HEMORRHOIDS
ATE381353T1 (de) Verbesserungen in oder an kontrastmitteln
BR9711663A (pt) M-tod e composi-Æo para tratamento de substrato umedecidos
HUP0103621A3 (en) Fentanyl composition for the treatment of acute pain
FI972205L (fi) cGmp-PDE:n estäjiä erektiohäiriön hoidossa
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
IL114229A0 (en) Compositions for applying active substances to or through the skin
DE59500555D1 (de) Mittel zur Wasserbehandlung
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
DE69527749D1 (de) Kugelförmige Aktivkohle zur Behandlung von Bauchentzündungen
IS4274A (is) Imidasópýridínsambönd til að nota við meðhöndlun sjúkdóma í meltingarvegi
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
FI963099A7 (fi) Vedenkäsittelymenetelmä ja -laite
GB9523335D0 (en) Improvements in or relating to skin treatment materials
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
DE60003550D1 (de) Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
NO982562D0 (no) Sammensetning for behandling av smerte